Cirio acts as legal adviser to Boule Diagnostics AB (publ) in connection with its fully secured preferential rights issue of approximately SEK 150 million. The rights issue is subject to approval by an extraordinary general meeting, to be held on November 1, 2022. The purpose of the rights issue is to finance the continued development, regulatory processes related to launch, as well as commercialization of the new hematology platform, including a new advanced 5-part system, a new 3-part system and a cloud connectivity solution.
Cirio’s team is headed by Annika Andersson, Head of Capital Markets and public M&A, and Per Hedman, Head of Life Science, Healthcare & Foods, with the assistance of, inter alia, Sebastian Iso-Kamula, Rebecka Tallberg, Julia Alander (Capital markets and public M&A), Hanna Tilus, Anja Nousiainen Hult, Avesta Rasool, Luka Rosko (Life Science and IP) and Niklas Sinander (Banking and finance).
For more information, please contact:
